The Fly | NRSN

Addressing High Unmet Medical Need: Neurosense targets Amyotrophic Lateral Sclerosis (ALS), a fatal neurodegenerative disease with significant unmet medical need and limited approved treatment options, positioning PrimeC for a high-demand market:PrimeC is designed to address multiple pathological pathways in ALS, including neuroinflammation, impaired RNA regulation, and oxidative stress, potentially offering a more comprehensive therapeutic benefit than single-target approaches.

Proprietary Combination Therapy Approach: PrimeC is a novel, patented oral combination of two existing drugs (ciprofloxacin and celecoxib), which leverages known safety profiles while aiming for synergistic therapeutic effects in ALS:The company holds Orphan Drug Designation in both the US and EU, and Fast Track Designation in the US for PrimeC in ALS, which can accelerate development, provide market exclusivity, and streamline regulatory review.

Multi-Modal Mechanism of Action: PrimeC is designed to address multiple pathological pathways in ALS, including neuroinflammation, impaired RNA regulation, and oxidative stress, potentially offering a more comprehensive therapeutic benefit than single-target approaches:Neurosense is focused on a specific biomarker, miR-17, which could facilitate patient stratification, demonstrate target engagement, and potentially lead to more effective clinical outcomes and personalized medicine approaches.

Clinical Trial Outcomes Risk: Failure of Neurosense's lead drug candidates, particularly PrimeC, to achieve primary or secondary endpoints in ongoing or future clinical trials, or the emergence of unexpected safety concerns, could lead to delays, additional costs, or the complete abandonment of development programs.

Regulatory Approval Pathways Risk: Inability to secure timely and necessary regulatory approvals from health authorities like the FDA or EMA for its drug candidates, or significant delays in the approval process, which would prevent or postpone the commercialization of its treatments.

Capital Availability Risk: The company's ability to raise sufficient additional capital to fund its extensive and expensive research, development, and clinical trial activities, potentially leading to financial distress, dilution for existing shareholders, or the cessation of operations if funding cannot be secured.